Pair Name	Triptolide, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2B33.4]	Leukemia		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Down-regulation	Expression	NFE2L2	hsa4780
	Down-regulation	Expression	GPX4	hsa2879
In Vitro Model	K-562	Blast phase chronic myelogenous leukemia	Homo sapiens (Human)	CVCL_0004
	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
Result	The present study indicated that Nrf2 served a critical role in leukemia cell resistance to DOX and triptolide‑induced ferroptosis and suggested a potential strategy of combination therapy using triptolide and DOX in leukemia treatment.

Pair Name	Triptolide, Carboplatin
Partner Name	Carboplatin
Disease Info	[ICD-11: 2C30]	Melanoma		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Down-regulation	Activity	NR1H2	hsa7376
In Vitro Model	A-375	Amelanotic melanoma	Homo sapiens (Human)	CVCL_0132
	B16	Mouse melanoma	Mus musculus (Mouse)	CVCL_F936
In Vivo Model	A375 cells were resuspended in 40% Matrigel (BD Biosciences) on ice, and then injected subcutaneously into the right axilla of the nude mice.
Result	This study reveals the NER inhibitor TPL which has great potential in treating melanoma, either alone or in combination with CBP.

Pair Name	Triptolide, ABT-199
Partner Name	ABT-199
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BID	hsa637
	Up-regulation	Expression	PMAIP1	hsa5366
	Up-regulation	Expression	BBC3	hsa27113
	Up-regulation	Expression	BCL2L11	KEGG ID N.A.
In Vitro Model	MV4-11	Childhood acute monocytic leukemia	Homo sapiens (Human)	CVCL_0064
	MOLM-13	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_2119
	U-937	Adult acute monocytic leukemia	Homo sapiens (Human)	CVCL_0007
	THP-1	Childhood acute monocytic leukemia	Homo sapiens (Human)	CVCL_0006
	KG-1a	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_1824
In Vivo Model	5-6 week-old female BALB/C nude mice (18–20 g; Beijing HFK bioscience Co. Ltd.) were injected subcutaneously with 5.8×10⁶ MOLM-13 cells at the right flank of mice.
Result	These findings suggest that the regimen combining TPL and ABT-199 might be active against AML by inducing robust apoptosis through reciprocal regulation of anti- and proapoptotic Bcl-2 family proteins, therefore providing a strong rationale for the clinical investigation of this combination regimen for the treatment of AML.

Pair Name	Triptolide, Gefitinib
Partner Name	Gefitinib
Disease Info	[ICD-11: 2C25.Z]	Lung cancer		Investigative
Biological Phenomena	Inhibition-->Epithelial-mesenchymal transition
Gene Regulation	Up-regulation	Expression	CDH1	hsa999
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	SNAI1	hsa6615
	Down-regulation	Expression	VIM	hsa7431
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
Result	The present results indicated that the combination of TP and TKIs may be a promising therapeutic strategy to treat patients with NSCLCs harboring EGFR mutations.

Pair Name	Triptolide, Cetuximab
Partner Name	Cetuximab
Disease Info	[ICD-11: 2C25.Z]	Lung cancer		Investigative
Gene Regulation	Down-regulation	Expression	EGFR	hsa1956
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
	NCI-H1299	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0060
	NCI-H520	Lung squamous cell carcinoma	Homo sapiens (Human)	CVCL_1566
	UM-SCC-6	Tongue squamous cell carcinoma	Homo sapiens (Human)	CVCL_7773
In Vivo Model	To establish xenografts of cancer cell lines, a suspension of 5×10⁶ H1299, UM-SCC6 cancer cells in 0.1 mL RPMI 1640 was injected into the subcutaneous dorsa of mice at the proximal midline.
Result	Cet-TPL represents a potent targeting therapeutic agent against EGFR-overexpressing NSCLC and others.